The present Competitive Intelligence Report about tissue growth factors
provides a competitor evaluation in the field of molecules such as proteins,
peptides, antibodies, DNA, RNA, cells and small molecules directly or
indirectly stimulating tissue growth as of December 2009. Purchase of the
downloadable pdf report includes a 6-month online access to the data of the
report and any updates since the publication date. Credentials to access the
database will be sent by e-mail and allow online work with the project data to
print or export an individual report.
The classical tissue factors typically are proteins used for tissue repair and
growth stimulation. Among the approved products are the growth factors PDGF,
IGF, EGF, BMP and FGF. One of the commercially most successful growth factors
is BMP-2 from Medtronic and Pfizer (ex Wyeth) with annual sales of nearly US$
800 mln and prospect for further growth by use in additional indications.
Growth factors are used for treatment of growth failure, skin wounds and
ulcers, corneal damage, oral mucositis or to stimulate bone growth. Further
growth factors such as HGF, VEGF, TGF, NGF, GDF and quite a number of
neurotrophic factors are under development. Apart from proteins as the
classical drugs, other classes of compounds are also under development such as
small molecules to stimulate growth factor receptors or antibodies to block
inhibitory pathways, thereby inducing functional recovery. Furthermore,
engineered peptides mimicking growth factors, cells engineered to express
growth factors or simply plasmids for growth factors are under development.
The report includes a compilation of currently active projects in research and
development of proteins, peptides, antibodies, DNA, RNA, cells and small
molecules directly or indirectly stimulating tissue growth and repair.
Competitor projects are listed in a tabular format providing information on:
Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
Growth Factors for Bone, Dental, Cartilage and Tendon Repair
Nerve Growth Factor (NGF)
Neurotrophic Growth Factors
Various Other Growth Factors
About La Merie
Companies mentioned in the report are:
Acceleron
Acologix
Acorda Therapeutics
ActoGeniX
Advitech
Alizyme
Alnylam Pharmaceuticals
Alseres Pharmaceuticals
Ambrx
Amgen
AnGes MG
Angion Biomedica
ARCA biopharma
Argenta Biotechnologies
Ark Therapeutics
ArmaGen Technologies
Astellas Pharma
Asterion
Auckland Uniservices
Baxter
Beijing SL Pharmaceuticals
Bharat Biotech
Bioactive Bone Substitutes (BBS)
Biogen Idec
Biopharm
BioMimetic Therapeutics
Bio-Sidus
Biosurface Engineering Technologies
Biovitrum
Bone Biologics
Bonenta
BrainStorm Cell Therapeutics
C3 Jian
Capstone Therapeutics
CardioVascular BioTherapeutics
Cardium Therapeutics
Celgene
NeNeRx Biopharma
CeraPedics
Ceregene
Cytomedix
Daewoong Pharmaceutical Co.
Daiichi Sankyo
DePuy Spine
Dompe
Dr. Reddy' s Laboratories
Edward Life Sciences
Eli Lilly
ENKAM
Gene Vector Laboratory
Genzyme
GI Company
GlaxoSmithKline (GSK)
Immuron
Insmed
Ipsen
Johnson & Johnson (Ortho-McNeil Pharmaceuticals)
Kaken Pharmaceutical Co
Kirin (Kyowa Hakko Kirin Pharma)
Kolon Life Sciences
Krenitsky Pharmaceuticals
Kringle Pharmaceuticals
Kuros Biosurgery
Lay Line Genomics
Lupin Pharmaceuticals
Maruho
Medtronic
Merck & Co
Merck Serono
Metabolic Pharmaceuticals
Mitsubishi Tanabe Pharma
Neuren Pharmaceuticals
Neurobiological Technologies
NeuroNova
Neurosearch
Neurotech
Nobel Biocare
NsGene
Osteohealth
Oxford Biomedica
Oy Lx Therapies
Pfizer (Wyeth)
Phage Biotechnology
Phytopharm
Renovo
Roche
Sangamo Biosciences
Sanofi-Aventis
Scil Proteins
Scil Technology
Shire
Sinobiomed
Spectrum Pharmaceuticals
Stem Cell Therapeutics
Taisho Toyama Pharmaceutical Co
Takeda Pharmaceutical Co
Teva Pharmaceutical Industries (CoGenesys)
TissueGene
ToolGen
Tornier
Transition Therapeutics
Trillium Therapeutics
Tripep
Trophogen
UCB
Uni-Bio Science Group
USV
Vical
ViroMed
Zelos Therapeutics
Zymogenetics
Competitor Analysis: Tissue Growth Factors published by La Merie Publishing in December 30, 2009. This report consists of 57 Pages and the price starts from US $ 1131.
Press Release
BMP-2 from Medtronic and Pfizer (ex Wyeth) one of most successful tissue growth factors with annual sales of nearly US$ 800 mln
February 10th, 2010
Global Information would like to present a market research report, "Competitor Analysis: Tissue Growth Factors" by La Merie Publishing.
The classical tissue factors typically are proteins used for tissue repair and growth stimulation. Among the approved products are the growth factors PDGF, IGF, EGF, BMP and FGF. One of the commercially most successful growth factors is BMP-2 from Medtronic and Pfizer (ex Wyeth) with annual sales of nearly US$ 800 mln and prospect for further growth by use in additional indications. Growth factors are used for treatment of growth failure, skin wounds and ulcers, corneal damage, oral mucositis or to stimulate bone growth. Further growth factors such as HGF, VEGF, TGF, NGF, GDF and quite a number of neurotrophic factors are under development. Apart from proteins as the classical drugs, other classes of compounds are also under development such as small molecules to stimulate growth factor receptors or antibodies to block inhibitory pathways, thereby inducing functional recovery. Furthermore, engineered peptides mimicking growth factors, cells engineered to express growth factors or simply plasmids for growth factors are under development.
